Prompt screening in combination with CYP21A2 genetic analyses, enables clinicians to manage severe cases in the neonatal period promptly, even before the appearance of any electrolyte imbalance and/or urgent adrenal crisis. The gene discussed is CYP21A2; the disease is acute adrenal insufficiency.